Catheter Precision Finalizes Strategic Cardiac Acquisition

Catheter Precision ( (VTAK) ) has shared an announcement.

In February 2025, Catheter Precision, Inc. formed a subsidiary, Cardionomix, Inc., to acquire assets from Cardionomic, Inc., which had ceased operations. On April 18, 2025, Cardionomix entered into an agreement to purchase assets related to a late-stage treatment for acute decompensated heart failure, including patents and trademarks for the Cardiac Pulmonary Nerve Simulation System. The acquisition was finalized on May 5, 2025, with Catheter Precision issuing 1,000,000 restricted shares and Cardionomix providing a $1.5 million promissory note. This strategic acquisition aims to enhance Catheter Precision’s portfolio in cardiac care, although it involves financial obligations and potential equity dilution for stakeholders.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.

VTAK’s overall stock score reflects significant challenges in financial performance, particularly in achieving profitability and generating positive cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages. Valuation remains unattractive due to ongoing losses and a negative P/E ratio. While the corporate event of an executive stock option plan is positive, it does not materially improve the current financial and technical outlook.

To see Spark’s full report on VTAK stock, click here.

More about Catheter Precision

Catheter Precision, Inc. operates in the medical device industry, focusing on developing innovative solutions for cardiac care. The company has a market focus on advanced treatment technologies for heart conditions, including acute decompensated heart failure.

Average Trading Volume: 171,864

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.53M

For a thorough assessment of VTAK stock, go to TipRanks’ Stock Analysis page.